Search

Displaying results 7331 - 7340 of 7654 in total
  1. Drug

    AVI-5126

    go.drugbank.com/drugs/DB05726
    Investigational

    AVI-526 is an improved formulation of [AVI-4557], developed for use on Vein Grafts before use in Heart by-Pass Graft Surgery.

  2. Drug

    OSI-930

    go.drugbank.com/drugs/DB05913
    Investigational

    OSI-930 is an orally active inhibitor of two clinically validated targets: c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2).

  3. Drug

    GS-441524

    go.drugbank.com/drugs/DB15686
    Investigational

    GS-441524 is an adenosine nucleotide analog antiviral, similar to [remdesivir].[A203057,L13239] This molecule was patented in 2009.

  4. Drug

    Droxidopa

    go.drugbank.com/drugs/DB06262
    ApprovedInvestigational

    The racaemic form (dl-threo-3,4-dihydroxyphenylserine) has also been used, and has been investigated in the treatment of orthostatic hypotension.

  5. Drug

    Inakalant

    go.drugbank.com/drugs/DB20424
    Investigational

    Inakalant has a monoisotopic molecular weight of 446.25 Da.

  6. Drug

    Nalorphine

    go.drugbank.com/drugs/DB11490
    ExperimentalVet approved

    It acts at two opioid receptors—at the mu receptor it has antagonistic effects, and at the kappa receptors it exerts high-efficacy agonistic characteristics.

  7. Drug

    Alteminostat

    go.drugbank.com/drugs/DB19620
    Investigational

    Alteminostat has a monoisotopic molecular weight of 492.28 Da.

  8. Drug

    Gemilukast

    go.drugbank.com/drugs/DB19882
    Investigational

    Gemilukast has a monoisotopic molecular weight of 601.26 Da.

  9. Drug

    Idetrexed

    go.drugbank.com/drugs/DB21469
    Investigational

    Idetrexed has a monoisotopic molecular weight of 647.22 Da.

  10. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.